Delving into the Latest Updates on Daigepurui Biotechnology (Suzhou) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Urogenital Diseases

Radiopharmaceuticals and diagnostic agent

Small molecule drug

Fluorescent dyes

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3

Top 5 Drug Type	Count

Radiopharmaceuticals and diagnostic agent	2
Small molecule drug	1
Fluorescent dyes	1

Top 5 Target	Count

Folate receptor	1
FOLR1 x Folate receptor	1
PSMA(Prostate-specific membrane antigen)	1

Ⅰ期阶段：主要研究目的：评估DGPR1008在健康受试者中单次给药的安全性、耐受性和药代动力学特征。次要研究目的：根据安全性和药代动力学结果评估DGPR1008的最大耐受剂量（MTD）和临床Ⅱ期推荐剂量（RP2D）。 Ⅱ期阶段：主要研究目的：评估DGPR1008在患者中单次给药的安全性和药代动力学特征。次要研究目的：评估DGPR1008联合近红外荧光成像设备检测在患者手术中的成像的有效性。

[Translation]

Phase I stage: Main study objectives: To evaluate the safety, tolerability and pharmacokinetic characteristics of a single dose of DGPR1008 in healthy subjects. Secondary study objectives: To evaluate the maximum tolerated dose (MTD) and clinical phase II recommended dose (RP2D) of DGPR1008 based on safety and pharmacokinetic results. Phase II stage: Main study objectives: To evaluate the safety and pharmacokinetic characteristics of a single dose of DGPR1008 in patients. Secondary study objectives: To evaluate the effectiveness of imaging in patients during surgery using DGPR1008 combined with near-infrared fluorescence imaging equipment.

Start Date21 Jun 2024

Sponsor / Collaborator

Daigepurui Biotechnology (Suzhou) Co., Ltd.

CTR20260155

/ Not yet recruitingPhase 2

PSMA靶向荧光造影剂DGPR1008用于机器人辅助前列腺根治术术中成像的安全性、有效性的临床Ⅱ期研究

[Translation] A Phase II clinical study on the safety and efficacy of the PSMA-targeted fluorescent contrast agent DGPR1008 for intraoperative imaging in robot-assisted radical prostatectomy.

主要研究目的：评估DGPR1008联合机器人手术控制系统，在机器人辅助前列腺根治术（Robot-Assisted Radical Prostatectomy RARP）术中荧光成像的有效性。次要研究目的：评估DGPR1008联合近红外荧光成像设备，在前列腺根治术后经组织病理学检测切缘阳性（PSM）的比率；评估DGPR1008在患者中单次给药的安全性。探索性研究目的：评估肿瘤背景比（TBR）。

[Translation]

Primary Study Objective: To evaluate the effectiveness of DGPR1008 in conjunction with a robotic surgical control system for fluorescence imaging during robot-assisted radical prostatectomy (RARP). Secondary Study Objectives: To evaluate the rate of positive surgical margins (PSM) detected by histopathological examination after RARP using DGPR1008 in conjunction with near-infrared fluorescence imaging; to evaluate the safety of a single dose of DGPR1008 in patients. Exploratory Study Objective: To evaluate the tumor background ratio (TBR).

Start Date-

Sponsor / Collaborator

Daigepurui Biotechnology (Suzhou) Co., Ltd.

100 Clinical Results associated with Daigepurui Biotechnology (Suzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Daigepurui Biotechnology (Suzhou) Co., Ltd.

Login to view more data

100 Deals associated with Daigepurui Biotechnology (Suzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Daigepurui Biotechnology (Suzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DGPR1008 ( PSMA )	Prostatic Cancer More	Phase 2
CN121378257 ( FOLR1 x Folate receptor )Patent Mining	Visible Lesion More	Discovery
WO2026036843 ( Folate receptor )Patent Mining	Neoplasms More	Discovery